COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203
<p dir="ltr">We read with interest the comments by Javeria Malik and Laksh Kumar1 on our published article “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”.2 We acknowledge their appreciation of the fact that this work primarily aimed to address an...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513528803622912 |
|---|---|
| author | Dr Rasha Kaddoura (17823434) |
| author2 | Dr Ashfaq Patel (17823437) |
| author2_role | author |
| author_facet | Dr Rasha Kaddoura (17823434) Dr Ashfaq Patel (17823437) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dr Rasha Kaddoura (17823434) Dr Ashfaq Patel (17823437) |
| dc.date.none.fl_str_mv | 2024-03-01T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2024.102379 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/COMMENT_ON_Revisiting_Beta-Blocker_Therapy_in_Heart_Failure_with_Preserved_Ejection_Fraction_Current_Problems_in_Cardiology_2023_doi_https_doi_org_10_1016_j_cpcardiol_2023_102203/25038281 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Beta-Blocker Therapy Heart failure therapy Left ventricular ejection fraction (LVEF) |
| dc.title.none.fl_str_mv | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">We read with interest the comments by Javeria Malik and Laksh Kumar1 on our published article “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”.2 We acknowledge their appreciation of the fact that this work primarily aimed to address an important gap in evidence related to the use of beta-blocker therapy in heart failure with preserved ejection fraction (HFpEF). We hereby wish to re-emphasize that although this article is classified as a narrative review, we performed a comprehensive literature search using MEDLINE and EMBASE databases (through Ovid interface) and utlizing broad key terms, without conducting a systematic review. Although the narrative reviews explicitly recognize that they may not include all relevant literature on a topic,3 we included all the studies that complied with our intended goal or main inclusion criterion, i.e., review of studies that enrolled patients with left ventricular ejection fraction (LVEF) according to the current definition of 50% or above. However, it was realized that many studies recruited patients with LVEF >40%, hence we opted to only consider the studies where the mean LVEF was 50% or above.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102379" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102379</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_2e8673f98ee85edda4acc49418381f2d |
| identifier_str_mv | 10.1016/j.cpcardiol.2024.102379 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25038281 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203Dr Rasha Kaddoura (17823434)Dr Ashfaq Patel (17823437)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesBeta-Blocker TherapyHeart failure therapyLeft ventricular ejection fraction (LVEF)<p dir="ltr">We read with interest the comments by Javeria Malik and Laksh Kumar1 on our published article “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”.2 We acknowledge their appreciation of the fact that this work primarily aimed to address an important gap in evidence related to the use of beta-blocker therapy in heart failure with preserved ejection fraction (HFpEF). We hereby wish to re-emphasize that although this article is classified as a narrative review, we performed a comprehensive literature search using MEDLINE and EMBASE databases (through Ovid interface) and utlizing broad key terms, without conducting a systematic review. Although the narrative reviews explicitly recognize that they may not include all relevant literature on a topic,3 we included all the studies that complied with our intended goal or main inclusion criterion, i.e., review of studies that enrolled patients with left ventricular ejection fraction (LVEF) according to the current definition of 50% or above. However, it was realized that many studies recruited patients with LVEF >40%, hence we opted to only consider the studies where the mean LVEF was 50% or above.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102379" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102379</a></p>2024-03-01T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2024.102379https://figshare.com/articles/journal_contribution/COMMENT_ON_Revisiting_Beta-Blocker_Therapy_in_Heart_Failure_with_Preserved_Ejection_Fraction_Current_Problems_in_Cardiology_2023_doi_https_doi_org_10_1016_j_cpcardiol_2023_102203/25038281CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/250382812024-03-01T03:00:00Z |
| spellingShingle | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 Dr Rasha Kaddoura (17823434) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Beta-Blocker Therapy Heart failure therapy Left ventricular ejection fraction (LVEF) |
| status_str | publishedVersion |
| title | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 |
| title_full | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 |
| title_fullStr | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 |
| title_full_unstemmed | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 |
| title_short | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 |
| title_sort | COMMENT ON “Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction”, Current Problems in Cardiology (2023), doi: https://doi.org/10.1016/j.cpcardiol.2023.102203 |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Beta-Blocker Therapy Heart failure therapy Left ventricular ejection fraction (LVEF) |